Day 2 - Saturday, 26 September 2026
8am to 7pm

7.30am to 7.55am

Registration

7.55am to 8am

Day 2 Opening Remarks

Session 6 – Moderators: Dr. Mohammed Al-Saeedi and Dr. Alaaeldin Shablak

8am to 8.15am

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA5): Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (mPDAC): Primary analysis from the phase 3 RASolute 302 study.

Dr. Kakil Rasul

Senior Consultant Medical Oncologist, NCCCR

8.15am to 8.30am

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary: Peri-Operative Treatment With Immunotherapy in Resectable Gastroesophageal Cancer.

Dr. Mohamed Sir Elkhatim Hamid Consultant Medical Oncologist, NCCCR

8.30am to 8.45am

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary: Promising New Drug Development Platform in Gastroesophageal Cancer.

Dr. Meeloud Aldardouri

Specialist Medical Oncologist, NCCCR

8.45am to 9am

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA4000): Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with embolization-eligible unresectable hepatocellular carcinoma (HCC).

Dr. Alaaeldin Shablak Consultant Medical Oncologist, NCCCR

9am to 9.15am

Gastrointestinal Cancer—Colorectal and Anal (Abstract LBA4000): Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.

Dr. Mai Mostafa

Consultant Medical Oncologist, NCCCR

9.15am to 9.30am

PANELDISCUSSION

Session 7 – Moderators: Dr Kakil Rasul, Dr. Hampig Kourie

9.30am to 9.45am

Gastrointestinal Cancer—Colorectal and Anal: Neoadjuvant vs Adjuvant Immunotherapy for Microsatellite Instability-High Colon Cancer.

Dr. Hampig Kourie

Assistant Professor, Hematology- oncology department, Faculty of Medicine, Saint Joseph University,

Beirut, Lebanon

9.45am to 10am

Gastrointestinal Cancer—Colorectal and Anal (Abstract LBA3503): BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Dr. Rebaz Haji Ali

Medical Oncologist, Hiwa Oncology Center, Sulaymaniyah, Iraq

10am to 10.15am

Gastrointestinal Cancer—Colorectal and Anal (Abstract LBA3517): AZUR-1: A phase II study of neoadjuvant dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer.

Dr. Aleem Akram

Associate Consultant, Medical Oncologist, NCCCR

10.15am to 10.30am

Gastrointestinal Cancer—Colorectal and Anal: Treatment Beyond First-Line Chemoimmunotherapy for Metastatic Anal Cancer.

Dr. Wamda Abdalla Associate Consultant Medical Oncologist, NCCCR

10.30am to 10.45am

Gastrointestinal Cancer—Colorectal and Anal:

Nonoperative Management After Neoadjuvant

Immunotherapy in Microsatellite Instability-High Localized Colorectal Cancer—One Size Fits All?

Dr. Ahmed Abdalhadi

Specialist, Oncologist, NCCCR

10.45am to 11am

PANELDISCUSSION

11am to 11.30 am

Welcome and Opening Ceremony

Celebrating Years of Dedication

• Dr. Reyad Mohsen - Senior Consultant Medical Oncologist, NCCCR
• Dr. Asma El Hassan - Senior Consultant Medical Oncologist, NCCCR
• Dr. Ayman Allam - Senior Consultant Medical Oncologist, NCCCR

Honoring a Lasting Legacy

• Dr. Wafer Amen Dabdoob - Consultant, Cardiology, HH
• Dr. Rasha Khudair

Conference Group Photo

Dr. Mohamed Salem Al-Hassan

CEO & Medical Director, NCCCR. Chairman, Corporate Cancer Services, HMC

Dr. Mohammed Ussama Al- Homsi

Conference Chairman

Senior Consultant, Medical Oncology, Ministry of Public Health (MoPH)

Dr. Eric Small

President of ASCO 2025-2026

(Pre- Recorded)

Dr. Anas Hamad

Chairman of Organizing Committee Deputy Chief of Drug Supply, HMC

11.30am to 12.35pm

Prayer & Lunch Break

Session 8 – Moderators: Dr. Ehab Massad and Dr. Aladdin Kanbour

12.35pm to 12.50pm

Lung Cancer—Non-Small Cell Metastatic (Abstract 8506):

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab

(P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP- Lung05 study.

Dr. Ammar Madani Associate Consultant Medical Oncologist, NCCCR

12.50pm to 1.05pm

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract 8004): Redefining lung cancer screening eligibility: Smoking duration vs. pack-years in a national VA cohort of nearly 1 million patients.

Dr. Reyad Mohsen

Senior Consultant Medical Oncologist

1.05pm to 1.20pm

Lung Cancer—Non-Small Cell Metastatic (Abstract LBA8500): Sunvozertinib monotherapy versus platinum- based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).

Dr. Muhammed Hajmusa Specialist, Medical Oncologist, NCCCR

1.20pm to 1.35pm

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract 8000): Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).

Dr. Muhammad Abubakar

Clinical Fellow, Medical Oncologist, NCCCR

1.35pm to 1.50pm

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers (Abstract LBA3): Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial.

Dr. Majd Aldwairi

Clinical Fellow, Medical Oncologist, NCCCR

1.50pm to 2.05pm

PANELDISCUSSION

Session 9 – Moderators: Dr. Khalid Balaraj, Dr. Mohammed Ussama Al Homsi and Dr. Khalid Al Rumaihi

2.05pm to 2.20pm

Genitourinary Cancer—Kidney and Bladder(Abstract 4504): Feasibility and safety results from RAD-IO: A multi- stage trial of durvalumab with chemoradiotherapy with 5- fluorouracil and mitomycin C in patients with muscle- invasive bladder cancer.

Dr. Mohamed Riyas

Senior Consultant Radiation Oncologist, NCCCR

2.20pm to 2.35pm

Genitourinary Cancer—Kidney and Bladder(Abstract 4507): Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.

Dr. Hassan Aakel

Specialist, Medical Oncologist, NCCCR

2.35pm to 2.50pm

Genitourinary—Prostate, Testicular, Penile (Abstract LBA1): Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study.

Dr. Mary-Ellen Taplin

Institute Physician and Director of Clinical Research for the Lank Center for Genitourinary Oncology

Dana-Farber Cancer Institute, Boston, USA

*PI of the PROTEUS phase 3 study

2.50pm to 3.05pm

PANELDISCUSSION

3.05pm to 3.25pm

Prayer & Coffee Break

Session 10 – Moderators: Dr. Anas Hamad and Dr. Hebatalla Afifi

3.25pm to 3.40pm

Prevention, Risk Reduction, and Genetics (Abstract 10505): Prospective prostate cancer screening in germline pathogenic variant carriers: The PATROL study.

Dr. Reem Jawad Al Sulaiman

Senior Consultant Genetic Counselor, NCCCR

3.40pm to 3.55pm

Quality Care/Health Services Research (Abstract 11000): The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.

Dr. Anas Hamad

Deputy Chief of Drug Supply, HMC

3.55pm to 4.10pm

Care Delivery/Models of Care (Abstract 1507): Follow- up of outpatients taking oral anticancer drugs in the multidisciplinary community hospital ONCORAL care plan.

Dr. Amaal Gulied

Clinical Pharmacy Specialist, NCCCR

4.10pm to 4.25pm

Quality Care/Health Services Research (Abstract 12000): Dexamethasone reduction or omission with NEPA and olanzapine for HEC: A phase III trial.

Dr. Arwa Osama

Clinical Pharmacist, NCCCR

4.25pm to 4.40pm

Quality Care/Health Services Research (Abstract 11005): Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real- world patients receiving therapy for metastatic solid tumors.

Dr. Randa Al-Okka

Senior Pharmacist, NCCCR

4.40pm to 4.55pm

Developmental Therapeutics—Immunotherapy (Abstract 2502): DART (NCI/SWOG S1609):

Comprehensive results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Mr. Alwaleed A AlIbrahim

Clinical Research Specialist, NCCCR

4.55pm to 5.10pm

PANELDISCUSSION

Session 11 – Moderators: Dr. Azza Hassan and Dr. Saad Eziada and Ms. Zainab Idris

5.10pm to 5.25pm

Medical Education and Professional Development (Abstract 9020): Psychological burden and burnout among regional healthcare providers communicating hereditary tumor findings: A multi-institutional communication skills

training implementation study.

Dr. Abdelhamid Afana

Senior Clinical Psychologist, NCCCR

5.25pm to 5.40pm

Care Delivery/Models of Care (Abstract 1508): Essential but unaffordable: Real-world costs of WHO essential

cancer medicines in a low-income setting.

Dr. Azar Saleem

Consultant, Palliative Care, NCCCR

5.40pm to 5.55pm

Symptom Science and Palliative Care (Abstract LBA12001): Gabapentin plus tramadol versus tramadol alone for chemoradiotherapy-induced oral mucositis pain in head and neck cancer: Results of a randomized

phase III trial.

Dr. Sair Saleh Ibrahim

Specialist, Palliative Care, NCCCR

5.55pm to 6.10pm

Symptom Science and Palliative Care (Abstract 12010): Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight

Loss (BWEL) trial.

Ms. Shanti Pappachan

Clinical Nurse Specialist, NCCCR

6.10pm to 6.25pm

Symptom Science and Palliative Care (Abstract LBA12008): SUPPORT+ digital self-management and clinical support for advanced cancer: A randomized

controlled trial.

Ms. Mais Abo Afifa

Clinical Nurse Specialist, NCCCR

6.25pm to 6.40pm

PANELDISCUSSION

6.40pm to 7pm

Closing Ceremony

Poster Presentations and Winner Announcement

Dr. Mohammed Ussama Al Homsi Conference Chairman

Senior Consultant, Medical Oncology, Ministry of Public Health (MoPH)

Dr. Anas Hamad

Chairman of Organizing Committee Deputy Chief of Drug Supply, HMC​​